Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis

Canadian Journal of Hospital Pharmacy

Volumn 63, Issue 3, 2010, Pages 196-206

  Van De Vijsel, Lyndsay M ^a   Walker, Sandra A N ^b   Walker, Scott E ^b   Yamashita, Sharon ^b   Simor, Andrew ^b   Hladunewich, Michelle ^b  

^a ST BONIFACE GENERAL HOSPITAL   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Continuous venovenous hemodialysis; Pharmacokinetics; Vancomycin

Indexed keywords

CREATININE; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; APACHE; AREA UNDER THE CURVE; ARTICLE; BLOOD FLOW; BODY WEIGHT; CONTINUOUS HEMODIALYSIS; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; RECOMMENDED DRUG DOSE; ULTRAFILTRATION; URINE VOLUME;

EID: 84055213987     PISSN: 00084123     EISSN: None     Source Type: Journal    
DOI: 10.4212/cjhp.v63i3.915     Document Type: Article

References (59)

1. Kutsogiannis D. Continuous venovenous hemodiafiltration for renal failure and sepsis. CMAJ 2000;162(4):537-538. (Pubitemid 30112000)
2. Garnacho-Montero J, Ortiz-Leyba C, Herrera-Melero I, Aldabó- Pallás T, Cayuela-Dominguez A, Marquez-Vacaro JA, et al. Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched cohort study. J Antimicrob Chemother 2008;61(2):436-441.
3. Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997;111(3):676-685. (Pubitemid 27132946)
4. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118(1):146-155. (Pubitemid 30485502)
5. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998;244(5):379-386. (Pubitemid 28513125)
6. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003;36(11):1418-1423. (Pubitemid 36702876)
7. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115(2):462-474. (Pubitemid 29083057)
8. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005;111(23):e394-e434.
9. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39(9):1267-1284. (Pubitemid 39458512)
10. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171(4):388-416.
11. Hidayat L, Hsu D, Quist R, Shriner K, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Arch Intern Med 2006;166(19):2138-2144. (Pubitemid 44631403)
12. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66(1):82-98.
13. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009;49(4):507-514.
14. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52(4):1330-1336. (Pubitemid 351521995)
15. Moise-Broder P, Forrest A, Birmingham M. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004;43(13):925-942. (Pubitemid 39447034)
16. Joy M, Matzke G, Frye R, Palevsky P. Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am J Kidney Dis 1998;31(6):1019-1027. (Pubitemid 28265200)
17. Davies SP, Azadian BS, Kox WJ, Brown EA. Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis. Nephrol Dial Transplant 1992;7(8):848-854.
18. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005;44(10):1009-1034. (Pubitemid 41356389)
19. DelDot ME, Lipman J, Tett SE. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol 2004;58(3):259-268. (Pubitemid 39209059)
20. Reetze-Bonorden P, Böhler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations. Clin Pharmacokinet 1993;24(5):362-379. (Pubitemid 23135684)
21. Boucher B, Kuhl D, Hickerson W. Pharmacokinetics of systemically administered antibiotics in patients with thermal injury. Clin Infect Dis 1992;14(2):458-463.
22. Weinbren MJ. Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother 1999;44(3):319-327. (Pubitemid 29425682)
23. Brater DC, Bawdon RE, Anderson SA, Purdue GF, Hunt JL. Vancomycin elimination in patients with burn injury. Clin Pharmacol Ther 1986;39(6):631-634. (Pubitemid 16097301)
24. Rybak M, Albrecht L, Berman J, Warbasse L, Svensson C. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 1990;34(5):792-795. (Pubitemid 20142400)
25. Dell'Aquila AM, McCulloch JA, Mamizuka EM, Santos SR, Pereira CA. Serum levels of vancomycin should be monitored in burn patients. Burns 2004;30(4):386-7. (Pubitemid 38622454)
26. Garrelts JC, Peterie JD. Altered vancomycin dose vs. serum concentration relationship in burn patients. Clin Pharmacol Ther 1988;44(1):9-13.
27. Dailly E, Le Floch R, Deslandes G, Pannier M, Jolliet R. Influence of glomerular filtration rate on the clearance of vancomycin administered by continuous infusion in burn patients. Int J Antimicrob Agents 2008;31(6):537-539.
28. Zokufa H, Solem L, Rodvold K, Crossley K, Fischer J, Rotschafer J. The influence of serum albumin and alpha 1-acid glycoprotein on vancomycin protein binding in patients with burn injuries. J Burn Care Rehabil 1989;10(5):425-428. (Pubitemid 19250620)
29. Knaus W, Draper E, Wagner D, Zimmerman J. APACHE II: a severity of disease classification system. Crit Care Med 1985;13(10):818-829. (Pubitemid 15250137)
30. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006;42 Suppl 1:S35-S39. (Pubitemid 41832063)
31. Rocker G, Cook D, Sjokvist P, Weaver B, Finfer S, McDonald E, et al. Clinician predictions of intensive care unit mortality. Crit Care Med 2004;32(5):1149-1154. (Pubitemid 38620983)
32. Ratheiser K, Schiefermeier M, Kranz A, Kramer L, Madl C, Schenk P, et al. Sudden increase in ICU-mortality rate: a look behind the stage applying continuous quality improvement [abstract]. Crit Care 1997;1(Suppl 1):P130.
33. Ghahramani N, Shadrou S, Hollenbeak C. A systematic review of continuous renal replacement therapy and intermittent haemodialysis in management of patients with acute renal failure. Nephrology 2008;13(7):570-578.
34. Tolwani AJ, Campbell RC, Stofan BS, Lai KR, Oster RA, Wille KM. Standard versus high-dose CVVHDF for ICU-related acute renal failure. J Am Soc Nephrol 2008;19(6):1233-1238.
35. Waikar S, Curhan G, Wald R, McCarthy E, Chertow G. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol 2006;17(4):1143-1150.
36. Brar H, Olivier J, Lebrun C, Gabbard W, Fulop T, Schmidt D. Predictors of mortality in a cohort of intensive care unit patients with acute renal failure receiving continuous renal replacement therapy. Am J Med Sci 2008;335(5):342-347.
37. Ibrahim EH, Ward S, Sherman G, Kollef MH. A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting. Chest 2000;117(5):1434-42. (Pubitemid 30321602)
38. Smith RL, Meixler SM, Simberkoff MS. Excess mortality in critically ill patients with nosocomial bloodstream infections. Chest 1991;100(1):164-167.
39. Bercault N, Boulain T. Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. Crit Care Med 2001;29(12):2303-2309. (Pubitemid 34038163)
40. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002;162(19):2229-2235. (Pubitemid 35231593)
41. Vallés J, Pobo A, García-Esquirol O, Mariscal D, Real J, Fernández R. Excess ICU mortality attributable to ventilator-associated pneumonia: the role of early vs late onset. Intensive Care Med 2007;33(8):1363-1368. (Pubitemid 47101716)
42. Polard E, Le Bouquin V, Le Corre P, Kerebel C, Trout H, Feuillu A, et al. Non steady state and steady state PKS Bayesian forecasting and vancomycin pharmacokinetics in ICU adult patients. Ther Drug Monit 1999;21(4):395-403. (Pubitemid 29350417)
43. Llopis-Salvia P, Jiménez-Torres N. Population pharmacokinetic parameters of vancomycin in critically ill patients. J Clin Pharm Ther 2006;31(5):447-454. (Pubitemid 44337293)
44. del Mar Fernández de Gatta Garcia M, Revilla N, Calvo MV, Dominguez-Gil A, Sánchez Navarro A. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med 2007;33(2):279-285.
45. Golper TA, Noonan HM, Elzinga L, Gilbert D, Brummett R, Anderson JL, et al. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther 1988;43(5):565-570.
46. Blouin R, Bauer L, Miller D, Record K, Griffin W. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982;21(4):575-580. (Pubitemid 12070524)
47. Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986;11(4):257-282. (Pubitemid 16050520)
48. Depaepe P, Belpaire F, Buylaert W. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 2002;41(14):1135-1151. (Pubitemid 35398690)
49. Roberts J, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006;45(8):755-773.
50. Pea F, Porreca L, Baraldo M, Furlanut M. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000;45(3):329-335. (Pubitemid 30139241)
51. Santré C, Leroy O, Simon M, Georges H, Guery B, Beuscart C, et al. Pharmacokinetics of vancomycin during continuous hemodiafiltration. Intensive Care Med 1993;19(6):347-350. (Pubitemid 23284799)
52. Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001;45(9):2460-2467. (Pubitemid 32801896)
53. Kitzis M, Goldstein F. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin Microbiol Infect 2006;12(1):92-95. (Pubitemid 43372248)
54. Grof T, Barrett M, Schmelzer T, Christmas A, Norton H, Sing R. A retrospective comparison of vancomycin continuous infusion and intermittent dosing in surgery patients with pneumonia. Chest 2007;132(4):497S.
55. Vuagnat A, Stern R, Lotthe A, Schuhmacher H, Duong M, Hoffmeyer P, et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther 2004;29(4):351-357. (Pubitemid 39062165)
56. James J, Palmer S, Levine D, Rybak M. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother 1996;40(3):696-700. (Pubitemid 26071537)
57. Pea F, Furlanut M, Negri C, Pavan F, Crapis M, Cristini F, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother 2009;53(5):1863-1867.
58. Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother 2009;63(5):1050-1057.
59. Boereboom FT, Ververs FF, Blankestijn PJ, Savelkoul TJ, van Dijk A. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Intensive Care Med 1999;25(10):1100-1104. (Pubitemid 29525065)